RG7834 是一种高度选择性 HBV 口服抑制剂，在 dHepaRG 细胞中，可抑制 HBV 抗原 HBeAg、HBsAg和 HBV DNA，IC50值分别为 2.6、2.8 和 3.2 nM。

RG7834 is a highly selective and orally bioavailable inhibitor of HBV(HBsAg and HBeAg and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells).

RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable inhibitor of HBV, RG7834 ((S)-(+)-64) potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells. RG7834 has no activity against CYP3A4, CYP2D6, CYP2C9 (IC50s >50 μM) or hERG channel.

In HBV-infected human liver chimeric uPA-SCID mice,RG7834 shows anti-HBV efficacy. RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, and with a half-life of 4.9 h in mice.

2072057-17-9

C22H27NO6

401.45

RO 7020322

DMSO:125 mg/mL (311.37 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years